These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 18628067)

  • 21. Histone deacetylase inhibitors: biology and mechanism of action.
    Mehnert JM; Kelly WK
    Cancer J; 2007; 13(1):23-9. PubMed ID: 17464243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone-deacetylase inhibitors for the treatment of cancer.
    Lindemann RK; Gabrielli B; Johnstone RW
    Cell Cycle; 2004 Jun; 3(6):779-88. PubMed ID: 15153801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.
    Tan J; Cang S; Ma Y; Petrillo RL; Liu D
    J Hematol Oncol; 2010 Feb; 3():5. PubMed ID: 20132536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylases and epigenetic therapies of hematological malignancies.
    Mercurio C; Minucci S; Pelicci PG
    Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospects: histone deacetylase inhibitors.
    Dokmanovic M; Marks PA
    J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
    Hutt DM; Roth DM; Marchal C; Bouchecareilh M
    Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?
    Koutsounas I; Giaginis C; Theocharis S
    World J Gastroenterol; 2013 Feb; 19(8):1173-81. PubMed ID: 23482354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone deacetylase inhibitors.
    Marks PA; Richon VM; Miller T; Kelly WK
    Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination Therapies Targeting HDAC and IKK in Solid Tumors.
    Vancurova I; Uddin MM; Zou Y; Vancura A
    Trends Pharmacol Sci; 2018 Mar; 39(3):295-306. PubMed ID: 29233541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents.
    Budillon A; Di Gennaro E; Bruzzese F; Rocco M; Manzo G; Caraglia M
    Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):119-34. PubMed ID: 18221057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential of histone deacetylase inhibitors in lung cancer.
    Aparicio A
    Clin Lung Cancer; 2006 Mar; 7(5):309-12. PubMed ID: 16640801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and development of SAHA as an anticancer agent.
    Marks PA
    Oncogene; 2007 Feb; 26(9):1351-6. PubMed ID: 17322921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
    Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
    Balakin KV; Ivanenkov YA; Kiselyov AS; Tkachenko SE
    Anticancer Agents Med Chem; 2007 Sep; 7(5):576-92. PubMed ID: 17896917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
    Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
    Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Histone-deacetylases inhibitors: from TSA to SAHA].
    Peixoto P; Lansiaux A
    Bull Cancer; 2006 Jan; 93(1):27-36. PubMed ID: 16455503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention.
    Ganai SA
    Curr Drug Targets; 2018; 19(6):593-601. PubMed ID: 27231104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing histone deacetylase inhibitors as anti-cancer therapeutics.
    Venugopal B; Evans TR
    Curr Med Chem; 2011; 18(11):1658-71. PubMed ID: 21428881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer.
    Amnekar RV; Khan SA; Rashid M; Khade B; Thorat R; Gera P; Shrikhande SV; Smoot DT; Ashktorab H; Gupta S
    World J Gastroenterol; 2020 Feb; 26(6):598-613. PubMed ID: 32103870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.